Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: A randomized, double-blind, placebo-controlled trial

Pharmacotherapy

Volumn 23, Issue 7, 2003, Pages 823-834

  Grijalva, Israel ^a,d   Guízar Sahagún, Gabriel ^a   Castañeda Hernández, Gilberto ^c   Mino, Dolores ^b   Maldonado Julián, Héctor ^a   Vidal Cantú, Guadalupe ^c   Ibarra, Antonio ^a   Serra, Omar ^a   Salgado Ceballos, Hermelinda ^a   Arenas Hernández, Rita ^c  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE; NIFEDIPINE; PLACEBO;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FISHER EXACT TEST; GASTRITIS; HEADACHE; HUMAN; HYPERPHAGIA; INSOMNIA; LIVER TOXICITY; LONG TERM CARE; MALE; MEMORY DISORDER; MOTOR PERFORMANCE; MUSCLE CRAMP; NAUSEA; NERVOUSNESS; PAIN; PARESTHESIA; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SENSATION; SENSORIMOTOR FUNCTION; SIDE EFFECT; SPINAL CORD INJURY; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASOSPASM; VERTIGO; XEROSTOMIA;

4-AMINOPYRIDINE; ADMINISTRATION, ORAL; ADULT; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; POTASSIUM CHANNEL BLOCKERS; SENSORY THRESHOLDS; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 0038043570     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.7.823.32731     Document Type: Article

References (52)

1. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the second national acute spinal cord injury study. N Engl J Med 1990;322:1405-11.
2. Coleman WP, Benzel D, Cahill DW, et al. A critical appraisal of the reporting of the national acute spinal cord injury studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 2000;13:185-99.
3. Potter PJ, Hayes KC, Segal JL, et al. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. Neurotrauma 1998;15:837-49.
4. van der Bruggen MA, Huisman HB, Beckerman H, Bertelsmann FW, Polman CH, Lankhorst GJ. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001;248:665-71.
5. Blight AR. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma 1985;2:299-315.
6. Blight AR, Decrescito V. Morphometric analysis of experimental spinal cord injury in the cat: the relation of injury intensity to survival of myelinated axons. Neuroscience 1986;19:321-41.
7. Salgado-Ceballos H, Guizar-Sahagun G, Feria-Velasco A, et al. Spontaneous long-term remyelination after traumatic spinal cord injury in rats. Brain Res 1998;782:126-35.
8. Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:570-2.
9. Blight AR, Gruner JA. Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 1987;82:145-59.
10. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989;22:47-52.
11. Blight AR, Toombs JP, Bauer MS, Widmer WR. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 1991;8:103-19.
12. Waxman SG. Aminopyridines and the treatment of spinal cord injury. J Neurotrauma 1993;10:19-24.
13. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77:553-62.
14. Shi R, Kelly TM, Blight AR. Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. Exp Neurol 1997;148:495-501.
15. Gruner JA, Yee AK. 4-Aminopyridine enhances motor evoked potentials following graded spinal cord compression injury in rats. Brain Res 1999;816:446-56.
16. Bunge RP, Puckett WR, Becerra JL, Marcillo A, Quencer RM. Observations on the pathology of human spinal cord injury: a review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol 1993;59:75-89.
17. Blight AR. Cellular morphology of chronic spinal cord injury in the cat: analysis of myelinated axons by line-sampling. Neuroscience 1983;10:521-43.
18. Lundh H, Thesleff S. The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol 1977;42:411-12.
19. Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-84.
20. Yu K, Rong W, Li J Neurophysiological evidence of spared upper motor conduction fibers in clinically complete spinal cord injury: discomplete SCI in rats. J Neurol Sci 2001;189:23-36.
21. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993;10:1-18.
22. Hayes KC, Blight AR, Potter PJ, et al. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 1993;31:216-24.
23. Hayes KC, Potter PJ, Wolfe DL, Hsieh JT, Delaney GA, Blight AR. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994;11:433-46.
24. Qiao J, Hayes KC, Hsieh JT, Potter PJ, Delaney GA. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury. J Neurotrauma 1997;14:135-49.
25. Segal JL, Brunnemann SR 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans. J Spinal Cord Med 1998;21:200-4.
26. Segal JL, Pathak MS, Hernandez JP, Himber PL, Brunnermann SR, Charter RS. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999;19:713-23.
27. Potter PJ, Hayes KC, Hsieh JT, Delaney GA, Segal JL. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998;36:147-55.
28. Wolfe DL, Hayes KC, Hsieh JT, Potter PJ. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial. J Neurotrauma 2001;18:757-71.
29. Maynard FM Jr, Bracken MB, Creasey G, et al. International standards for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Spinal Cord 1997;35:266-74.
30. Catz A, Itzkovich M, Agranov E, Ring H, Tamir A. SCIM-spinal cord independence measure: a new disability scale for patients with spinal cord lesions. Spinal Cord 1997;35:850-6.
31. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247-54.
32. Sumida M, Fujimoto M, Tokuhiro A, Tominaga T, Magara A, Uchida R. Early rehabilitation effect for traumatic spinal cord injury. Arch Phys Med Rehabil 2001;82:391-5.
33. Segal JL, Warner AL, Brunnermann SR, Bunten DC. 4-aminopyridine influences heart rate variability in long-standing spinal cord injury. Am J Ther 2002;9:29-33.
34. de Craen AJ, Kaptchuk TJ, Tijssen JG, Kleijnen J. Placebos and placebo effects in medicine: historical overview. J R Soc Med 1999;92:511-15.
35. Thompson WG. Placebos: a review of the placebo response. Am J Gastroenterol 2000;95:1637-43.
36. Benson H, McCallie DP Jr. Angina pectoris and the placebo effect. N Engl J Med 1979;300:1424-9.
37. Anonymous. Gabapentin in partial epilepsy: UK gabapentin study group. Lancet 1990;333:1114-17.
38. Downer SM, Cody MM, McCluskey P, et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 1994;309:86-9.
39. Stoessl AJ. Neurochemical and neuroreceptor imaging with PET in Parkinson's disease. Adv Neurol 2001;86:215-23.
40. Feinstein AR. An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann Intern Med 1983;99:843-8.
41. Kapfhammer JP. Axon sprouting in the spinal cord: growth promoting and growth inhibitory mechanisms. Anat Embryol (Berl) 1997;196:417-26.
42. Reddy H, Narayanan S, Matthews PM. Relating axonal injury to functional recovery in MS. Neurology 2000;54:236-9.
43. Velmahos GC, Degiannis E, Hart K, Souter I, Saadia R. Changing profiles in spinal cord injuries and risk factors influencing recovery after penetrating injuries. J Trauma 1995;38:334-7.
44. McKinley WO, Johns JS, Musgrove JJ. Clinical presentations, medical complications, and functional outcomes of individuals with gunshot wound-induced spinal cord injury. Am J Phys Med Rehabil 1999;78:102-7.
45. Segal JL, Milne N, Brunnemann SR. Gastric emptying is impaired in patients with spinal cord injury. Am J Gastroenterol 1995;90:466-70.
46. Abbracchio MP, Saffrey MJ, Hopker V, Burnstock G. Modulation of astroglial cell proliferation by analogues of adenosine and ATP in primary cultures of rat striatum. Neuroscience 1994;59:67-76.
47. Neary JT, Baker L, Jorgensen SL, Noremberg MD. Extracellular ATP induces stellation and increases glial fibrillary acidic protein content and DNA synthesis in primary astrocyte cultures. Acta Neuropathol (Berl) 1994;87:8-13.
48. Neary JT, Rathbone MP, Cattabeni F, Abbracchio MP, Burnstock G. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 1996;19:13-18.
49. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-71.
50. Van Diemen HA, Polman CH, Koetsier JC, Van Loenen AC, Nauta JJ, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16:195-204.
51. van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:123-30.
52. Segal JL, Brunnemann SR. 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury. Pharmacotherapy 1997;17:415-23.